Russell H. Swerdlow

Dr. Russell H. Swerdlow


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2017 in Journal of Alzheimer’s Disease
Verified
Journal Article
Open access
PDF file
RSRussell H. Swerdlow
Russell H. Swerdlow
Decades of research indicate mitochondria from Alzheimer’s disease (AD) patients differ from those of non-AD individuals. Initial studies revealed structural differences, and subsequent studies showed functional deficits. Observations of structure and function changes prompted investigators to consider the consequences, significance, and causes of AD-related mitochondrial dysfunction. Currently, extensive research argues mitochondria may mediate, drive, or contribute to a variety of AD pathologies. The perceived significance of these mitochondrial changes continues to grow, and many currently believe AD mitochondrial dysfunction represents a reasonable therapeutic target. Debate continues over the origin of AD mitochondrial changes. Some argue amyloid-β (Aβ) induces AD mitochondrial dysfunction, a view that does not challenge the amyloid cascade hypothesis and that may in fact help explain that hypothesis. Alternatively, data indicate mitochondrial dysfunction exists independent of Aβ, potentially lies upstream of Aβ deposition, and suggest a primary mitochondrial cascade hypothesis that assumes mitochondrial pathology hierarchically supersedes Aβ pathology. Mitochondria, therefore, appear at least to mediate or possibly even initiate pathologic molecular cascades in AD. This review considers studies and data that inform this area of AD research.

1 August 2014 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
RSRussell H. Swerdlow
Russell H. Swerdlow
JBJeffrey M. Burns
Jeffrey M. Burns
SKShaharyar M. Khan
Shaharyar M. Khan

3 June 2010 in Journal of Alzheimer’s Disease
Verified
Journal Article
Open access
PDF file
RSRussell H. Swerdlow
Russell H. Swerdlow
JBJeffrey M Burns
Jeffrey M Burns
SKShaharyar M Khan
Shaharyar M Khan
We first proposed the mitochondrial cascade hypothesis of sporadic Alzheimer's disease (AD) in 2004. Our core assumptions were a person's genes determine baseline mitochondrial function and durability, this durability determines how mitochondria chan

24 January 2019 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
JOJudit M. Perez Ortiz
Judit M. Perez Ortiz
RSRussell H. Swerdlow
Russell H. Swerdlow
Dysfunction of cell bioenergetics is a common feature of neurodegenerative diseases, the most common of which is Alzheimer's disease (AD). Disrupted energy utilization implicates mitochondria at its nexus. This review summarizes some of the evidence that points to faulty mitochondrial function in AD and highlights past and current therapeutic development efforts. Classical neuropathological hallmarks of disease (β‐amyloid and τ) and sporadic AD risk genes (APOE) may trigger mitochondrial disturbance, yet mitochondrial dysfunction may incite pathology. Preclinical and clinical efforts have overwhelmingly centred on the amyloid pathway, but clinical trials have yet to reveal clear‐cut benefits. AD therapies aimed at mitochondrial dysfunction are few and concentrate on reversing oxidative stress and cell death pathways. Novel research efforts aimed at boosting mitochondrial and bioenergetic function offer an alternative treatment strategy. Enhancing cell bioenergetics in preclinical models may yield widespread favourable effects that could benefit persons with AD.Linked Articles: This article is part of a themed section on Therapeutics for Dementia and Alzheimer's Disease: New Directions for Precision Medicine. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.18/issuetoc

1 December 2011 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
RSRussell H. Swerdlow
Russell H. Swerdlow

4 December 2017 in Alzheimer's & Dementia: Translational Research & Clinical Interventions
Verified
Journal Article
Open access
MTMatthew K. Taylor
Matthew K. Taylor
DSDebra K. Sullivan
Debra K. Sullivan
JMJonathan D. Mahnken
Jonathan D. Mahnken
JBJeffrey M. Burns
Jeffrey M. Burns
RSRussell H. Swerdlow
Russell H. Swerdlow
Introduction: We assessed the feasibility and cognitive effects of a ketogenic diet (KD) in participants with Alzheimer's disease. Methods: The Ketogenic Diet Retention and Feasibility Trial featured a 3‐month, medium‐chain triglyceride–supplemented KD followed by a 1‐month washout in clinical dementia rating (CDR) 0.5, 1, and 2 participants. We obtained urine acetoacetate, serum β‐hydroxybutyrate, food record, and safety data. We administered the Alzheimer's Disease Assessment Scale‐cognitive subscale and Mini–Mental State Examination before the KD, and following the intervention and washout. Results: We enrolled seven CDR 0.5, four CDR 1, and four CDR 2 participants. One CDR 0.5 and all CDR 2 participants withdrew citing caregiver burden. The 10 completers achieved ketosis. Most adverse events were medium‐chain triglyceride–related. Among the completers, the mean of the Alzheimer's Disease Assessment Scale‐cognitive subscale score improved by 4.1 points during the diet ( P = .02) and reverted to baseline after the washout. Discussion: This pilot trial justifies KD studies in mild Alzheimer's disease.